Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Operating Expenses (2022 - 2025)

Historic Operating Expenses for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $3.7 million.

  • bioAffinity Technologies' Operating Expenses fell 1353.62% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year decrease of 315.09%. This contributed to the annual value of $18.3 million for FY2024, which is 7433.79% up from last year.
  • As of Q3 2025, bioAffinity Technologies' Operating Expenses stood at $3.7 million, which was down 1353.62% from $3.8 million recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Operating Expenses peaked at $5.2 million during Q4 2024, and registered a low of $685279.0 during Q2 2022.
  • Moreover, its 4-year median value for Operating Expenses was $3.7 million (2025), whereas its average is $3.0 million.
  • Per our database at Business Quant, bioAffinity Technologies' Operating Expenses soared by 18011.68% in 2023 and then tumbled by 1561.51% in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Operating Expenses stood at $1.6 million in 2022, then soared by 180.12% to $4.6 million in 2023, then grew by 13.13% to $5.2 million in 2024, then dropped by 27.46% to $3.7 million in 2025.
  • Its Operating Expenses was $3.7 million in Q3 2025, compared to $3.8 million in Q2 2025 and $4.5 million in Q1 2025.